Search | IOVS | ARVO Journals

Showing 1 – 20 of 33

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

The impact of COVID-19 on visual acuity for nAMD patients treated with aflibercept in the UK

Clare Bailey; Marta Helena Gruszka-Goh; Andrew J Lotery; Romi Chhabra; Haralabos Eleftheriadis; Faruque Ghanchi; Colin Jones; Peter H Scanlon

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1336 – F0170. doi:

ARVO Annual Meeting Abstract June 2022

Characterizing anti-VEGF treatment patterns for neovascular age-related macular degeneration in the United Kingdom

Mishank Jain; Ronald Cantrell; Jaya Devi Chidambaram; Davneet Judge; Melanie Dodds; Sarah McGrory; Clare Bailey

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1315 – F0149. doi:

ARVO Annual Meeting Abstract June 2022

Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration

Jared Nielsen; Robert E MacLaren; Jeffrey S Heier; David Steel; Tsveta Ivanova; Sobha Sivaprasad; Paulo Stanga; Clare Bailey; Peter Charbel Issa; Luisa Mendonca; James Francis; Darin Curtiss; Jane Hughes; Nadia K Waheed

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1504. doi:

ARVO Annual Meeting Abstract June 2022

Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): Final study results from the European IRISS registry study

Ramin Khoramnia; Tunde Peto; Simon R Taylor; Joao Paulo Castro de Sousa; Lauren Hill; Clare Bailey; Usha Chakravarthy

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):2182 – F0245. doi:

ARVO Annual Meeting Abstract June 2022

Assessing the impact of COVID-19 on visual acuity for diabetic macular edema patients treated with aflibercept in the UK

Peter H Scanlon; Charlotte Frances Elizabeth Norridge; Rajarshi Mukherjee; Andrew J Lotery; Tunde Peto; Romi Chhabra; Clare Bailey; Haralabos Eleftheriadis; Faruque Ghanchi; Colin Jones

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3776 – F0197. doi:

Clinical Trials December 2021

Conversion of Central Subfield Thickness Measurements of Diabetic Macular Edema Across Cirrus and Spectralis Optical Coherence Tomography Instruments

PDF

Jennifer K. Sun; Kristin Josic; Michele Melia; Adam R. Glassman; Clare Bailey; Kakarla V. Chalam; Emily Y. Chew; Catherine Cukras; Sandeep Grover; Glenn J. Jaffe; Richard Lee; Jared S. Nielsen; Darby J. S. Thompson; Henry E. Wiley; Frederick L. Ferris, 3rd; for the DRCR Retina Network
TAGS: diabetic macular edema, eye, optical coherence tomography, sensitivity analysis
Trans. Vis. Sci. Tech.. 2021; 10(14):34. doi: https://doi.org/10.1167/tvst.10.14.34

Includes: Supplemental Content

Articles March 2021

Reliability of Retinal Pathology Quantification in Age-Related Macular Degeneration: Implications for Clinical Trials and Machine Learning Applications

PDF

Philipp L. Müller; Bart Liefers; Tim Treis; Filipa Gomes Rodrigues; Abraham Olvera-Barrios; Bobby Paul; Narendra Dhingra; Andrew Lotery; Clare Bailey; Paul Taylor; Clarisa I. Sánchez; Adnan Tufail
TAGS: age-related macular degeneration, machine learning, pathology, reliability, drusen, diagnostic imaging
Trans. Vis. Sci. Tech.. 2021; 10(3):4. doi: https://doi.org/10.1167/tvst.10.3.4

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2020

Real world outcomes for aflibercept in diabetic macula edema

Haralabos Eleftheriadis; Irene Mary Stratton; James S Talks; Peter Henry Scanlon; Shahram Kashani; Andrew J Lotery; Clare Bailey; Raj Mukherjee; Usha Chakravarthy

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3290. doi:

ARVO Annual Meeting Abstract June 2020

Incidence and prevalence of moderate to severe non-proliferative diabetic retinopathy within an English Screening Programme

Emily Fletcher; Clareece R Kerby; Irene Mary Stratton; Sobha Sivaprasad; Clare Bailey; Elvira Massó-González; Sonia Maruti; Michael Ehrlich; Victor Chong; Peter Henry Scanlon

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3830. doi:

ARVO Annual Meeting Abstract June 2020

Real-life long-term outcomes for patients treated with the 0.19 mg fluocinolone acetonide (FAc; ILUVIEN) intravitreal implant for DME: Three-year follow-up from the RegIstry Safety Study (IRISS) .

Ramin Khoramnia; Frank H J Koch; Usha Chakravarthy; Simon R Taylor; Joao Paulo Castro de Sousa; Clare Bailey

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4862. doi:

ARVO Annual Meeting Abstract July 2019

Real-world outcomes from the 3-year European ILUVIEN (0.19 mg fluocinolone acetonide implant) RegIstry Safety Study (IRISS)

Frank HJ Koch; Usha Chakravarthy; Ramin Khoramnia; Simon Taylor; Clare Bailey; João Sousa

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2622. doi:

ARVO Annual Meeting Abstract July 2019

Aflibercept in the real world – an EPR based clinical audit of patients with diabetic macular edema from 21 UK hospitals

Sajjad Mahmood; Irene Mary Stratton; Raj Mukherjee; James S Talks; Clare Bailey; Andrew Lotery; Shahram Kashani; Faruque Ghanchi; Salim Natha; Peter Henry Scanlon

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2626. doi:

ARVO Annual Meeting Abstract July 2019

Earlier intervention is associated with improved visual outcomes in patients with persistent or recurrent diabetic edema - Clinical insights from the ILUVIEN (fluocinolone acetonide) Registry Safety Study (IRISS)

Panos Vouzounis; Simon Taylor; Usha Chakravarthy; Clare Bailey; Frank HJ Koch; João Sousa

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2630. doi:

Retina February 2019

An Evaluation of a Battery of Functional and Structural Tests as Predictors of Likely Risk of Progression of Age-Related Macular Degeneration

PDF

D. Grant Robinson; Tom H. Margrain; Clare Bailey; Alison M. Binns
TAGS: age-related macular degeneration, dark adaptation, outcome measures, photopsia, retinal cone, severity of illness, vision, drusen, retina, eye
Invest. Ophthalmol. Vis. Sci.. 2019; 60(2):580-589. doi: https://doi.org/10.1167/iovs.18-25092

Includes: Supplemental Content

Retina September 2018

Low-Level Nighttime Light Therapy for Age-Related Macular Degeneration: A Randomized Clinical Trial

PDF

D. Grant Robinson; Tom H. Margrain; Matt J. Dunn; Clare Bailey; Alison M. Binns
TAGS: age-related macular degeneration, clinical trials, masks, phototherapy, ultraviolet therapy, outcome measures, drusen, safety, dark adaptation, disease progression
Invest. Ophthalmol. Vis. Sci.. 2018; 59(11):4531-4541. doi: https://doi.org/10.1167/iovs.18-24284

Includes: Supplemental Content

ARVO Annual Meeting Abstract July 2018

United Kingdom multicenter Medisoft™ electronic medical record real-world audit following implant of ILUVIEN ® (fluocinolone acetonide 190 µg) – the first 3-year results from the UK

Fahd Quhill; Clare Bailey; Usha Chakravarthy; Andrew Lotery; Geeta Menon; James S Talks

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1906. doi:

ARVO Annual Meeting Abstract July 2018

Audit of anti-VEGF injections for diabetic macula edema in 21 UK hospitals

Peter Henry Scanlon; Irene Stratton; Clare Bailey; Haralobos Eleftheriadis; Naren Dhingra; James S Talks; Tunde Peto

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3607. doi:

ARVO Annual Meeting Abstract June 2017

New staging of Acute Posterior Multifocal Placoid Pigment Epiteliopathy by using multimodal imaging

Ester Carreno; Tomas Burke; Colin Chu; Serena Salvatore; Richard W J Lee; Clare Bailey; Andrew D Dick; Adam H Ross

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5995. doi:

ARVO Annual Meeting Abstract June 2017

Progression from early/intermediate age-related macular degeneration to either geographic atrophy or choroidal neovascularisation in a large UK cohort

Usha Chakravarthy; Clare Bailey; Martin McKibbin; Sarah Rabhi; Anushini Muthutantri; Christopher Brittain; Jeffrey R Willis; Ronald A Cantrell

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2979. doi:

ARVO Annual Meeting Abstract June 2017

Clinical Features Predict Diabetic Retinopathy Progression

Cecilia S Lee; Aaron Y Lee; Doug Baughman; Atul Varma; Salim Natha; Louise Downey; Geeta Menon; Sajjad Mahmood; Usha Chakravarthy; David Paul Crabb; Alastair K Denniston; Clare Bailey; Adnan Tufail; Catherine A Egan

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4283. doi:

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

The impact of COVID-19 on visual acuity for nAMD patients treated with aflibercept in the UK

Characterizing anti-VEGF treatment patterns for neovascular age-related macular degeneration in the United Kingdom

Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration

Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): Final study results from the European IRISS registry study

Assessing the impact of COVID-19 on visual acuity for diabetic macular edema patients treated with aflibercept in the UK

Conversion of Central Subfield Thickness Measurements of Diabetic Macular Edema Across Cirrus and Spectralis Optical Coherence Tomography Instruments

Reliability of Retinal Pathology Quantification in Age-Related Macular Degeneration: Implications for Clinical Trials and Machine Learning Applications

Real world outcomes for aflibercept in diabetic macula edema

Incidence and prevalence of moderate to severe non-proliferative diabetic retinopathy within an English Screening Programme

Real-life long-term outcomes for patients treated with the 0.19 mg fluocinolone acetonide (FAc; ILUVIEN) intravitreal implant for DME: Three-year follow-up from the RegIstry Safety Study (IRISS) .

Real-world outcomes from the 3-year European ILUVIEN (0.19 mg fluocinolone acetonide implant) RegIstry Safety Study (IRISS)

Aflibercept in the real world – an EPR based clinical audit of patients with diabetic macular edema from 21 UK hospitals

Earlier intervention is associated with improved visual outcomes in patients with persistent or recurrent diabetic edema - Clinical insights from the ILUVIEN (fluocinolone acetonide) Registry Safety Study (IRISS)

An Evaluation of a Battery of Functional and Structural Tests as Predictors of Likely Risk of Progression of Age-Related Macular Degeneration

Low-Level Nighttime Light Therapy for Age-Related Macular Degeneration: A Randomized Clinical Trial

United Kingdom multicenter Medisoft™ electronic medical record real-world audit following implant of ILUVIEN ® (fluocinolone acetonide 190 µg) – the first 3-year results from the UK

Audit of anti-VEGF injections for diabetic macula edema in 21 UK hospitals

New staging of Acute Posterior Multifocal Placoid Pigment Epiteliopathy by using multimodal imaging

Progression from early/intermediate age-related macular degeneration to either geographic atrophy or choroidal neovascularisation in a large UK cohort

Clinical Features Predict Diabetic Retinopathy Progression

To View More...

You must be signed into an individual account to use this feature.